Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120111) titled 'A Study on Predicting Prostate Cancer Using Artificial Intelligence-Based Integrated Analytical Techniques' on March 9.
Study Type: Diagnostic test
Study Design:
Diagnostic test for accuracy
Primary Sponsor: Lishui Central Hospital
Condition:
Prostate Malignant Tumor
Intervention:
Gold Standard:Prostate biopsy pathology served as the gold standard for diagnosing prostate cancer in this study.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-10
Target Sample Size: Target condition:140;Difficult condition:20
Countries of Recruitment:
China
To know more, visit https:/...